Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gareth P Gregory

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Lancet (London, England)|November 16, 2024
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trialJeremy S Abramson, Matthew Ku, Mark Hertzberg, et al.
Blood Advances|June 10, 2026
Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLOJeremy S Abramson, William Townsend, Christopher P Fox, et al.
Nature Communications|March 7, 2017
Genomic characterisation of Eμ-Myc mouse lymphomas identifies Bcor as a Myc co-operative tumour-suppressor geneMarcus Lefebure, Richard W Tothill, Elizabeth Kruse, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2020
AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x<sub>L</sub>, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting ThrombocytopeniaSrividya B Balachander, Steven W Criscione, Kate F Byth, et al.
Nature Communications|December 19, 2018
Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemiaAdriana E Tron, Matthew A Belmonte, Ammar Adam, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Lancet (London, England)|November 16, 2024
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trialJeremy S Abramson, Matthew Ku, Mark Hertzberg, et al.
Blood Advances|June 10, 2026
Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLOJeremy S Abramson, William Townsend, Christopher P Fox, et al.
Nature Communications|March 7, 2017
Genomic characterisation of Eμ-Myc mouse lymphomas identifies Bcor as a Myc co-operative tumour-suppressor geneMarcus Lefebure, Richard W Tothill, Elizabeth Kruse, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2020
AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x<sub>L</sub>, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting ThrombocytopeniaSrividya B Balachander, Steven W Criscione, Kate F Byth, et al.
Nature Communications|December 19, 2018
Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemiaAdriana E Tron, Matthew A Belmonte, Ammar Adam, et al.
Pageof 4